Effectiveness of Protease Inhibitor/Nucleos(t)ide Reverse Transcriptase Inhibitor–Based Second-line Antiretroviral Therapy for the Treatment of Human Immunodeficiency Virus Type 1 Infection in Sub-Saharan Africa: A Systematic Review and Meta-analysis | Zendy

Alexander Stockdale | Zendy; Matthew J Saunders | Zendy; Mark Boyd | Zendy; Laura Bonnett | Zendy; Victoria Johnston | Zendy; Gilles Wandeler | Zendy; Annelot F. Schoffelen | Zendy; Laura Ciaffi | Zendy; Kristen A. Stafford | Zendy; Ann C. Collier | Zendy; Nicholas I. Paton | Zendy; Anna María Geretti | Zendy

Open Access

Effectiveness of Protease Inhibitor/Nucleos(t)ide Reverse Transcriptase Inhibitor–Based Second-line Antiretroviral Therapy for the Treatment of Human Immunodeficiency Virus Type 1 Infection in Sub-Saharan Africa: A Systematic Review and Meta-analysis

Author(s) -

Alexander Stockdale,

Matthew J Saunders,

Mark Boyd,

Laura Bonnett,

Victoria Johnston,

Gilles Wandeler,

Annelot F. Schoffelen,

Laura Ciaffi,

Kristen A. Stafford,

Ann C. Collier,

Nicholas I. Paton,

Anna María Geretti

Publication year - 2017

Publication title -

clinical infectious diseases

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 3.44

H-Index - 336

eISSN - 1537-6591

pISSN - 1058-4838

DOI - 10.1093/cid/cix1108

Subject(s) - medicine , interquartile range , confidence interval , viral load , population , protease inhibitor (pharmacology) , meta analysis , virology , drug resistance , immunology , antiretroviral therapy , virus , biology , environmental health , microbiology and biotechnology

In sub-Saharan Africa, 25.5 million people are living with human immunodeficiency virus (HIV), representing 70% of the global total. The need for second-line antiretroviral therapy (ART) is projected to increase in the next decade in keeping with the expansion of treatment provision. Outcome data are required to inform policy.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research